Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status

Melissa Rotunno, Xuezheng Sun, Jonine Figueroa, Mark E. Sherman, Montserrat Garcia-Closas, Paul Meltzer, Tyisha Williams, Sallie S. Schneider, D. J. Jerry, Xiaohong R. Yang, Melissa A. Troester

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

INTRODUCTION: Relationships of parity with breast cancer risk are complex. Parity is associated with decreased risk of postmenopausal hormone receptor-positive breast tumors, but may increase risk for basal-like breast cancers and early-onset tumors. Characterizing parity-related gene expression patterns in normal breast and breast tumor tissues may improve understanding of the biological mechanisms underlying this complex pattern of risk.

METHODS: We developed a parity signature by analyzing microRNA microarray data from 130 reduction mammoplasty (RM) patients (54 nulliparous and 76 parous). This parity signature, together with published parity signatures, was evaluated in gene expression data from 150 paired tumors and adjacent benign breast tissues from the Polish Breast Cancer Study, both overall and by tumor estrogen receptor (ER) status.

RESULTS: We identified 251 genes significantly upregulated by parity status in RM patients (parous versus nulliparous; false discovery rate = 0.008), including genes in immune, inflammation and wound response pathways. This parity signature was significantly enriched in normal and tumor tissues of parous breast cancer patients, specifically in ER-positive tumors.

CONCLUSIONS: Our data corroborate epidemiologic data, suggesting that the etiology and pathogenesis of breast cancers vary by ER status, which may have implications for developing prevention strategies for these tumors.

Original languageEnglish (US)
Pages (from-to)R74
JournalBreast cancer research : BCR
Volume16
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Parity
Estrogen Receptors
Breast Neoplasms
Neoplasms
Mammaplasty
Breast
Gene Expression
MicroRNAs
Genes
Hormones
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rotunno, M., Sun, X., Figueroa, J., Sherman, M. E., Garcia-Closas, M., Meltzer, P., ... Troester, M. A. (2014). Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status. Breast cancer research : BCR, 16(4), R74. https://doi.org/10.1186/bcr3689

Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status. / Rotunno, Melissa; Sun, Xuezheng; Figueroa, Jonine; Sherman, Mark E.; Garcia-Closas, Montserrat; Meltzer, Paul; Williams, Tyisha; Schneider, Sallie S.; Jerry, D. J.; Yang, Xiaohong R.; Troester, Melissa A.

In: Breast cancer research : BCR, Vol. 16, No. 4, 2014, p. R74.

Research output: Contribution to journalArticle

Rotunno, M, Sun, X, Figueroa, J, Sherman, ME, Garcia-Closas, M, Meltzer, P, Williams, T, Schneider, SS, Jerry, DJ, Yang, XR & Troester, MA 2014, 'Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status', Breast cancer research : BCR, vol. 16, no. 4, pp. R74. https://doi.org/10.1186/bcr3689
Rotunno, Melissa ; Sun, Xuezheng ; Figueroa, Jonine ; Sherman, Mark E. ; Garcia-Closas, Montserrat ; Meltzer, Paul ; Williams, Tyisha ; Schneider, Sallie S. ; Jerry, D. J. ; Yang, Xiaohong R. ; Troester, Melissa A. / Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status. In: Breast cancer research : BCR. 2014 ; Vol. 16, No. 4. pp. R74.
@article{9a0658839b30428bb4fde5f7c9378488,
title = "Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status",
abstract = "INTRODUCTION: Relationships of parity with breast cancer risk are complex. Parity is associated with decreased risk of postmenopausal hormone receptor-positive breast tumors, but may increase risk for basal-like breast cancers and early-onset tumors. Characterizing parity-related gene expression patterns in normal breast and breast tumor tissues may improve understanding of the biological mechanisms underlying this complex pattern of risk.METHODS: We developed a parity signature by analyzing microRNA microarray data from 130 reduction mammoplasty (RM) patients (54 nulliparous and 76 parous). This parity signature, together with published parity signatures, was evaluated in gene expression data from 150 paired tumors and adjacent benign breast tissues from the Polish Breast Cancer Study, both overall and by tumor estrogen receptor (ER) status.RESULTS: We identified 251 genes significantly upregulated by parity status in RM patients (parous versus nulliparous; false discovery rate = 0.008), including genes in immune, inflammation and wound response pathways. This parity signature was significantly enriched in normal and tumor tissues of parous breast cancer patients, specifically in ER-positive tumors.CONCLUSIONS: Our data corroborate epidemiologic data, suggesting that the etiology and pathogenesis of breast cancers vary by ER status, which may have implications for developing prevention strategies for these tumors.",
author = "Melissa Rotunno and Xuezheng Sun and Jonine Figueroa and Sherman, {Mark E.} and Montserrat Garcia-Closas and Paul Meltzer and Tyisha Williams and Schneider, {Sallie S.} and Jerry, {D. J.} and Yang, {Xiaohong R.} and Troester, {Melissa A.}",
year = "2014",
doi = "10.1186/bcr3689",
language = "English (US)",
volume = "16",
pages = "R74",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "4",

}

TY - JOUR

T1 - Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status

AU - Rotunno, Melissa

AU - Sun, Xuezheng

AU - Figueroa, Jonine

AU - Sherman, Mark E.

AU - Garcia-Closas, Montserrat

AU - Meltzer, Paul

AU - Williams, Tyisha

AU - Schneider, Sallie S.

AU - Jerry, D. J.

AU - Yang, Xiaohong R.

AU - Troester, Melissa A.

PY - 2014

Y1 - 2014

N2 - INTRODUCTION: Relationships of parity with breast cancer risk are complex. Parity is associated with decreased risk of postmenopausal hormone receptor-positive breast tumors, but may increase risk for basal-like breast cancers and early-onset tumors. Characterizing parity-related gene expression patterns in normal breast and breast tumor tissues may improve understanding of the biological mechanisms underlying this complex pattern of risk.METHODS: We developed a parity signature by analyzing microRNA microarray data from 130 reduction mammoplasty (RM) patients (54 nulliparous and 76 parous). This parity signature, together with published parity signatures, was evaluated in gene expression data from 150 paired tumors and adjacent benign breast tissues from the Polish Breast Cancer Study, both overall and by tumor estrogen receptor (ER) status.RESULTS: We identified 251 genes significantly upregulated by parity status in RM patients (parous versus nulliparous; false discovery rate = 0.008), including genes in immune, inflammation and wound response pathways. This parity signature was significantly enriched in normal and tumor tissues of parous breast cancer patients, specifically in ER-positive tumors.CONCLUSIONS: Our data corroborate epidemiologic data, suggesting that the etiology and pathogenesis of breast cancers vary by ER status, which may have implications for developing prevention strategies for these tumors.

AB - INTRODUCTION: Relationships of parity with breast cancer risk are complex. Parity is associated with decreased risk of postmenopausal hormone receptor-positive breast tumors, but may increase risk for basal-like breast cancers and early-onset tumors. Characterizing parity-related gene expression patterns in normal breast and breast tumor tissues may improve understanding of the biological mechanisms underlying this complex pattern of risk.METHODS: We developed a parity signature by analyzing microRNA microarray data from 130 reduction mammoplasty (RM) patients (54 nulliparous and 76 parous). This parity signature, together with published parity signatures, was evaluated in gene expression data from 150 paired tumors and adjacent benign breast tissues from the Polish Breast Cancer Study, both overall and by tumor estrogen receptor (ER) status.RESULTS: We identified 251 genes significantly upregulated by parity status in RM patients (parous versus nulliparous; false discovery rate = 0.008), including genes in immune, inflammation and wound response pathways. This parity signature was significantly enriched in normal and tumor tissues of parous breast cancer patients, specifically in ER-positive tumors.CONCLUSIONS: Our data corroborate epidemiologic data, suggesting that the etiology and pathogenesis of breast cancers vary by ER status, which may have implications for developing prevention strategies for these tumors.

UR - http://www.scopus.com/inward/record.url?scp=84964314053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964314053&partnerID=8YFLogxK

U2 - 10.1186/bcr3689

DO - 10.1186/bcr3689

M3 - Article

C2 - 25005139

AN - SCOPUS:84903807525

VL - 16

SP - R74

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 4

ER -